Recognition of AmacaThera’s leadership and landmark agreement with Pacira BioSciences for its long‑acting, opioid‑sparing anesthetic in post‑operative pain management Progressing AMT-143 to Phase 2 clinical development in 2026 Toronto, Ontario – February 11, 2026 — AmacaThera, a leading developer of next-generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a […]
AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera’s long-acting non-opioid anesthetic for post-operative pain AMT-143 leverages AmacaThera’s breakthrough tunable hydrogel platform, delivering sustained local release of ropivacaine AmacaThera and Pacira will collaborate on the Phase 2 clinical program, and Pacira will fund […]
Apply now – Deadline 5th November 2021 – Calls for the Tech and Innovation Booster track will open in Q1 2022.
DayOne focus on healthcare innovation driven by digital health solutions. Together with supporting partners, they define and deliver the Accelerator each year in a run that includes specific themes, such as value-based healthcare, patient-centered innovation, or diabetes & metabolism. DayOne 2022 edition is focused on pain management. Are you a startup with a creative solution […]
